# Defining the Optimal Cryoballoon Duration Therapy for Treatment of Atrial Fibrillation: Defining the Optimal Cryoballoon Duration Therapy for Treatment of Atrial Fibrillation: The 1-2-3 Study

> **NCT02074566** · NA · COMPLETED · sponsor: **Harald Verheij** · enrollment: 222 (actual)

## Conditions studied

- Atrial Fibrillation

## Interventions

- **OTHER:** Cryoballoon ablation

## Key facts

- **NCT ID:** NCT02074566
- **Lead sponsor:** Harald Verheij
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-08-14
- **Primary completion:** 2018-03-08
- **Final completion:** 2019-02-13
- **Target enrollment:** 222 (ACTUAL)
- **Last updated:** 2020-03-12

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02074566

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02074566, "Defining the Optimal Cryoballoon Duration Therapy for Treatment of Atrial Fibrillation: Defining the Optimal Cryoballoon Duration Therapy for Treatment of Atrial Fibrillation: The 1-2-3 Study". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT02074566. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*